| Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095 | Technology appraisal guidance |
| Abdominal aortic aneurysm | Quality standard |
| Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer TS ID 11831 | Technology appraisal guidance |
| Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833] | Technology appraisal guidance |
| Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance |
| Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia TS ID 11768 | Technology appraisal guidance |
| Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823 | Technology appraisal guidance |
| Acne | Quality standard |
| Adalimumab for treating early Dupuytren's contracture TS ID 11870 | Technology appraisal guidance |
| Adrenal dysfunction | Quality standard |
| Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care | Quality standard |
| Advocacy services for adults with health and social care needs | Quality standard |
| Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064] | Technology appraisal guidance |
| Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680 | Technology appraisal guidance |
| Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830 | Technology appraisal guidance |
| Ambulatory pulmonary artery pressure monitoring devices | Diagnostics guidance |
| Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion-positive advanced non-small-cell lung cancer [ID5110] | Technology appraisal guidance |
| Amivantamab with lazertinib for previously untreated
locally advanced or metastatic non-small-cell lung cancer TS ID 11842 | Technology appraisal guidance |
| Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192] | Technology appraisal guidance |
| Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer TS ID 10323 | Technology appraisal guidance |
| Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia | Medical technologies guidance |
| Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774 | Technology appraisal guidance |
| Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer TS ID 11802 | Technology appraisal guidance |
| Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052] | Technology appraisal guidance |
| Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable TS ID 11785 | Technology appraisal guidance |
| Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence TS ID 10650 | Technology appraisal guidance |
| Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203] | Technology appraisal guidance |
| Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894] | Technology appraisal guidance |
| Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152] | Technology appraisal guidance |
| Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793] | Technology appraisal guidance |
| Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794] | Technology appraisal guidance |
| Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212] | Technology appraisal guidance |
| Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6211] | Technology appraisal guidance |
| Belimumab with rituximab for treating systemic lupus erythematosus [ID3967] | Technology appraisal guidance |
| Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769 | Technology appraisal guidance |
| Benralizumab for previously treated severe nasal polyps [ID1659] | Technology appraisal guidance |
| Benralizumab for treating hypereosinophilic syndrome in people 12 years and over TS ID 11867 | Technology appraisal guidance |
| Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis TS ID 10591 | Technology appraisal guidance |
| Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550 | Technology appraisal guidance |
| Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959] | Technology appraisal guidance |
| BI 907828 for untreated dedifferentiated advanced liposarcoma TS ID 11860 | Technology appraisal guidance |
| Bimekizumab for treating ankylosing spondylitis TS ID 10334 | Technology appraisal guidance |
| Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592 | Technology appraisal guidance |
| Brentuximab vedotin in combination for untreated advanced classical Hodgkin lymphoma TS ID 11898 | Technology appraisal guidance |
| Bupivacaine–meloxicam for treating postoperative pain [ID2728] | Technology appraisal guidance |
| Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731] | Technology appraisal guidance |
| CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666 | Technology appraisal guidance |
| Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888 | Technology appraisal guidance |
| Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer TS ID 10555 | Technology appraisal guidance |
| Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214 | Technology appraisal guidance |
| Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145] | Technology appraisal guidance |
| Children and young people with disabilities and severe complex needs: integrated health and social care support | Quality standard |
| Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012] | Technology appraisal guidance |
| Cladribine for treating relapsing multiple sclerosis TS ID 11834 | Technology appraisal guidance |
| Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099] | Technology appraisal guidance |
| Crovalimab for treating paroxysmal nocturnal haemoglobinuria TS ID 10622 | Technology appraisal guidance |
| Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417) | Technology appraisal guidance |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839 | Technology appraisal guidance |
| Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838 | Technology appraisal guidance |
| Daratumumab for treating high-risk smouldering multiple myeloma [ID6214] | Technology appraisal guidance |
| Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable TS ID 10300 | Technology appraisal guidance |
| Daridorexant for treating insomnia disorder [ID3774] | Technology appraisal guidance |
| Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer TS ID 11909 | Technology appraisal guidance |
| Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy TS ID 11840 | Technology appraisal guidance |
| Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over TS ID 10392 | Technology appraisal guidance |
| Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154 | Technology appraisal guidance |
| Digitally-enabled therapy for tic disorders in children and young people | Medical technologies guidance |
| Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants | Interventional procedures guidance |
| Diverticular disease | Quality standard |
| Dostarlimab with chemotherapy for untreated and with niraparib for maintenance treatment of advanced non-mucinous epithelial ovarian, fallopian tube or primary peritoneal cancer TS ID 11876 | Technology appraisal guidance |
| Dulaglutide for treating type 2 diabetes [ID1451] | Technology appraisal guidance |
| Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years TS ID 11885 | Technology appraisal guidance |
| Dupilumab for treating moderate to severe chronic obstructive pulmonary disease TS ID 10741 | Technology appraisal guidance |
| Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736 | Technology appraisal guidance |
| Durvalumab (Imfinzi) with bevacizumab (Avastin) for high-risk adjuvant hepatocellular carcinoma [ID6146] | Technology appraisal guidance |
| Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation TS ID 11797 | Technology appraisal guidance |
| Durvalumab for maintenance treatment of recurrent or advanced endometrial cancer TS ID 11856 | Technology appraisal guidance |
| Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer TS ID 10554 | Technology appraisal guidance |
| Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073] | Technology appraisal guidance |
| Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery TS ID 11844 | Technology appraisal guidance |
| Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080] | Technology appraisal guidance |
| Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944] | Technology appraisal guidance |
| Durvalumab with concurrent chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906] | Technology appraisal guidance |
| Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124] | Technology appraisal guidance |
| Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855] | Technology appraisal guidance |
| Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097] | Technology appraisal guidance |
| Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097] | Technology appraisal guidance |
| Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830] | Technology appraisal guidance |
| Edaravone for treating amyotrophic lateral sclerosis TS ID 11869 | Technology appraisal guidance |
| Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046 | Technology appraisal guidance |
| Elafibranor for treating primary biliary cholangitis TS ID 11889 | Technology appraisal guidance |
| Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847 | Technology appraisal guidance |
| Empagliflozin for reducing death and hospitalisation from heart failure after acute myocardial infarction TS ID 11817 | Technology appraisal guidance |
| Empagliflozin for treating chronic kidney disease TS ID 10698 | Technology appraisal guidance |
| Encorafenib with binimetinib for treating BRAF V600E mutation-positive metastatic non-small-cell lung cancer [ID6177] | Technology appraisal guidance |
| Endometrial cancer (high risk, newly diagnosed) - pembrolizumab (with chemotherapy, adjuvant) [ID6207] | Technology appraisal guidance |
| Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer | Interventional procedures guidance |
| Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer TS ID 10718 | Technology appraisal guidance |
| Ensitrelvir for treating COVID-19 TS ID 11813 | Technology appraisal guidance |
| Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy TS ID 9716 | Technology appraisal guidance |
| Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TS ID 11899 | Technology appraisal guidance |
| Eplontersen for treating polyneuropathy caused by hereditary transthyretin-related amyloidosis TS ID 11901 | Technology appraisal guidance |
| Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037 | Technology appraisal guidance |
| Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827] | Technology appraisal guidance |
| Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806 | Technology appraisal guidance |
| Evobrutinib for treating relapsing multiple sclerosis TS ID 11864 | Technology appraisal guidance |
| Faricimab for treating macular oedema caused by retinal vein occlusion TS ID 11783 | Technology appraisal guidance |
| Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer TS ID 11859 | Technology appraisal guidance |
| Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133] | Technology appraisal guidance |
| Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726] | Technology appraisal guidance |
| Fruquintinib for previously treated metastatic colorectal cancer TS ID 11843 | Technology appraisal guidance |
| Futibatinib for treating advanced cholangiocarcinoma with FGFR2 fusion or rearrangement after systemic treatment TS ID 11874 | Technology appraisal guidance |
| Galcanezumab for migraine TS ID 10663 | Technology appraisal guidance |
| Gambling | Quality standard |
| Gantenerumab for treating early Alzheimer's disease TS ID 10668 | Technology appraisal guidance |
| Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072] | Technology appraisal guidance |
| Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772 | Technology appraisal guidance |
| Givinostat for treating Duchenne muscular dystrophy TS ID 9963 | Technology appraisal guidance |
| Givinostat for treating Duchenne muscular dystrophy TS ID 9963 | Technology appraisal guidance |
| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma TS ID 11800 | Technology appraisal guidance |
| Gosuranemab for treating progressive supranuclear palsy [ID1607] | Technology appraisal guidance |
| Gout | Quality standard |
| Guselkumab for treating moderately to severely active Crohn's disease TS ID 10614 | Technology appraisal guidance |
| Guselkumab for treating moderately to severely active ulcerative colitis TS ID 10713 | Technology appraisal guidance |
| Heart valve disease in adults | Quality standard |
| Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129] | Technology appraisal guidance |
| Hydromethylthionine mesylate for treating Alzheimer's disease TS ID 11890 | Technology appraisal guidance |
| Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720] | Technology appraisal guidance |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies TS ID 10330 | Technology appraisal guidance |
| Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922] | Technology appraisal guidance |
| Infant, children and young people's experience of health care | Quality standard |
| Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923] | Technology appraisal guidance |
| Insulin icodec for treating type 1 and type 2 diabetes TS ID 11770 | Technology appraisal guidance |
| Intravenous zanamivir for treating influenza in hospital [ID1196] | Technology appraisal guidance |
| Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190 | Technology appraisal guidance |
| Iptacopan for treating complement 3 glomerulopathy TS ID 10435 | Technology appraisal guidance |
| Isatuximab in combination for newly diagnosed multiple myeloma [ID3981] | Technology appraisal guidance |
| Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868] | Technology appraisal guidance |
| Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517] | Technology appraisal guidance |
| Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822 | Technology appraisal guidance |
| Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117] | Technology appraisal guidance |
| Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117] | Technology appraisal guidance |
| Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966] | Technology appraisal guidance |
| Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996 | Technology appraisal guidance |
| Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868 | Technology appraisal guidance |
| Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652 | Technology appraisal guidance |
| Lifileucel for previously treated unresectable or metastatic melanoma [ID3863] | Technology appraisal guidance |
| Linerixibat for treating pruritus in people with primary biliary cholangitis TS ID 10136 | Technology appraisal guidance |
| Linzagolix for treating pain caused by endometriosis TS ID 11886 | Technology appraisal guidance |
| Liposomal bupivacaine for treating postoperative pain [ID3799] | Technology appraisal guidance |
| Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017] | Technology appraisal guidance |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID3887] | Technology appraisal guidance |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869] | Technology appraisal guidance |
| LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844] | Technology appraisal guidance |
| Lonafarnib for treating progeria and progeroid laminopathies [ID3867] | Highly specialised technology |
| Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870] | Technology appraisal guidance |
| Lutetium oxodotreotide with octreotide for untreated advanced gastroenteropancreatic neuroendocrine tumours in people 15 years and over TS ID 11875 | Technology appraisal guidance |
| Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978] | Technology appraisal guidance |
| Managing symptoms with an uncertain cause | Quality standard |
| Marstacimab for treating severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over TS ID 11897 | Technology appraisal guidance |
| Masitinib with riluzole for treating amyotrophic lateral sclerosis TS ID 10728 | Technology appraisal guidance |
| Mavorixafor for treating WHIM syndrome ID3946 | Technology appraisal guidance |
| Mepolizumab for treating chronic obstructive pulmonary disease [ID1237] | Technology appraisal guidance |
| Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects | Interventional procedures guidance |
| Mirabegron for treating neurogenic detrusor overactivity in people aged 3 to 17 TS ID 10730 | Technology appraisal guidance |
| Mirikizumab for treating moderately to severely active Crohn's disease TS ID 11826 | Technology appraisal guidance |
| Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096] | Technology appraisal guidance |
| Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769] | Technology appraisal guidance |
| Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over TS ID 11777 | Technology appraisal guidance |
| Nemolizumab for treating moderate to severe atopic dermatitis in people aged 12 and over or prurigo nodularis in adults TS ID 10515 | Technology appraisal guidance |
| Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078] | Technology appraisal guidance |
| Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping TS ID 10593 | Technology appraisal guidance |
| Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523 | Technology appraisal guidance |
| Niraparib with dostarlimab for maintenance treatment of advanced or recurrent endometrial cancer | Technology appraisal guidance |
| Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab TS ID 11913 | Technology appraisal guidance |
| Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548 | Technology appraisal guidance |
| Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable stage 2 or 3B non-small-cell lung cancer TS ID 10543 | Technology appraisal guidance |
| Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over [ID6189] | Technology appraisal guidance |
| Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053] | Technology appraisal guidance |
| Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] | Technology appraisal guidance |
| Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer TS ID 10542 | Technology appraisal guidance |
| Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID 5102] | Technology appraisal guidance |
| Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659 | Technology appraisal guidance |
| Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma TS ID 10345 | Technology appraisal guidance |
| Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939] | Technology appraisal guidance |
| Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer TS ID 10631 | Technology appraisal guidance |
| Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia TS ID 11911 | Technology appraisal guidance |
| Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065] | Technology appraisal guidance |
| Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ] | Technology appraisal guidance |
| Ondansetron for treating alcohol-use disorder TS ID 11884 | Technology appraisal guidance |
| ONS-5010 for treating wet age-related macular degeneration TS ID 11792 | Technology appraisal guidance |
| Oral semaglutide for managing overweight and obesity [ID6188] | Technology appraisal guidance |
| Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223] | Technology appraisal guidance |
| Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328] | Technology appraisal guidance |
| OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152] | Highly specialised technology |
| Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128] | Technology appraisal guidance |
| Pain management (young people and adults) | Quality standard |
| Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846] | Technology appraisal guidance |
| Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer TS ID 10670 | Technology appraisal guidance |
| Palforzia for treating peanut allergy in children aged 1 to 3 TS ID 10510 | Technology appraisal guidance |
| Pancreatitis (including acute pancreatitis) | Quality standard |
| Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865 | Technology appraisal guidance |
| Pegvaliase for treating phenylketonuria [ID1110] | Technology appraisal guidance |
| Pelvic floor dysfunction | Quality standard |
| Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994] | Technology appraisal guidance |
| Pembrolizumab for neoadjuvant and adjuvant treatment of resectable stage 2 to 3B non-small-cell lung cancer [ID 5094] | Technology appraisal guidance |
| Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [ID6138] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer TS ID 10690 | Technology appraisal guidance |
| Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer TS ID 11852 | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808 | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer TS ID 10602 | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer TS ID 10602 | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID5094] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer TS ID 11858 | Technology appraisal guidance |
| Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853] | Technology appraisal guidance |
| Pembrolizumab with enfortumab vedotin for untreated locally advanced or metastatic urothelial cancer TS ID 10556 | Technology appraisal guidance |
| Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TS ID 11810 | Technology appraisal guidance |
| Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861 | Technology appraisal guidance |
| Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109] | Technology appraisal guidance |
| Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993] | Technology appraisal guidance |
| Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006] | Technology appraisal guidance |
| Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028] | Technology appraisal guidance |
| Pembrolizumab with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID4044] | Technology appraisal guidance |
| Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985] | Technology appraisal guidance |
| Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer TS ID 10705 | Technology appraisal guidance |
| Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer TS ID 11908 | Technology appraisal guidance |
| Pemigatinib for treating myeloproliferative neoplasms with an FGFR1 rearrangement TS ID 11780 | Technology appraisal guidance |
| Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587 | Technology appraisal guidance |
| Perioperative care | Quality standard |
| Pernicious anaemia | Quality standard |
| Phrenic nerve pacing for congenital central hypoventilation syndrome | Interventional procedures guidance |
| Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury | Interventional procedures guidance |
| Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors TS ID 10628 | Technology appraisal guidance |
| Pitolisant for treating narcolepsy in children and young people 6 to 17 years TS ID 11893 | Technology appraisal guidance |
| Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895] | Technology appraisal guidance |
| PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989] | Technology appraisal guidance |
| Prevention of dementia | Quality standard |
| Primary hyperparathyroidism | Quality standard |
| Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127] | Technology appraisal guidance |
| PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130 | Technology appraisal guidance |
| Ranibizumab port delivery system for treating diabetic macular oedema TS ID 10549 | Technology appraisal guidance |
| Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642 | Technology appraisal guidance |
| Readmission to ICU within 48hrs | Quality standard |
| REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443 | Technology appraisal guidance |
| Remdesivir for treating COVID-19 [ID3808] | Technology appraisal guidance |
| Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer TS ID 11851 | Technology appraisal guidance |
| Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320] | Technology appraisal guidance |
| Rivaroxaban for treating chronic heart failure [ID1462] | Technology appraisal guidance |
| Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819] | Technology appraisal guidance |
| Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764 | Technology appraisal guidance |
| Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763 | Technology appraisal guidance |
| Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996] | Technology appraisal guidance |
| Sabizabulin for treating COVID-19 TS ID 11814 | Technology appraisal guidance |
| Sacituzumab govitecan for treating unresectable metastatic urothelial cancer TS ID 10707 | Technology appraisal guidance |
| Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal | Quality standard |
| Safeguarding adults in care homes | Quality standard |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237 | Technology appraisal guidance |
| Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506] | Technology appraisal guidance |
| Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over TS ID 11846 | Technology appraisal guidance |
| Secondary care management of malignant hypertension | Quality standard |
| Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825] | Technology appraisal guidance |
| Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments [ID6193] | Technology appraisal guidance |
| Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options TS ID 11850 | Technology appraisal guidance |
| Semaglutide for treating type 2 diabetes (ID1450) | Technology appraisal guidance |
| Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer TS ID 11912 | Technology appraisal guidance |
| Setmelanotide for treating obesity caused by a rare genetic disorder in children aged 2 to 5 TS ID 11827 | Technology appraisal guidance |
| Shared decision-making: practical guidance for health and social care professionals | Quality standard |
| Sirolimus-eluting collagen implant for creating vascular access for haemodialysis in end-stage kidney disease TS ID 9147 | Technology appraisal guidance |
| Sleep disordered breathing | Quality standard |
| Social work interventions for adults with complex needs (including learning disabilities) and mental health needs | Quality standard |
| Sotagliflozin for treating type 2 diabetes [ID1657] | Technology appraisal guidance |
| Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955] | Technology appraisal guidance |
| Sparsentan for treating primary IgA nephropathy TS ID 11866 | Technology appraisal guidance |
| Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions | Medical technologies guidance |
| Spesolimab for preventing generalised pustular psoriasis flares TS ID 11789 | Technology appraisal guidance |
| SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280] | Technology appraisal guidance |
| Sternoclavicular joint replacement for arthritis | Interventional procedures guidance |
| STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278] | Technology appraisal guidance |
| STS101 for treating acute migraine TS ID 11782 | Technology appraisal guidance |
| Supporting independent living and preventing isolation in adults of working age with social care needs | Quality standard |
| Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082] | Technology appraisal guidance |
| Tazemetostat for treating relapsed or refractory follicular lymphoma after 2 or more treatments TS ID 11906 | Technology appraisal guidance |
| Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201] | Technology appraisal guidance |
| Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments TS ID 10684 | Technology appraisal guidance |
| Tenecteplase for thrombolytic treatment of acute ischaemic stroke TS ID 11871 | Technology appraisal guidance |
| Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition TS ID 10753 | Technology appraisal guidance |
| Test DG | Diagnostics guidance |
| Test347 | Technology appraisal guidance |
| The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound | Medical technologies guidance |
| Thyroid disease | Quality standard |
| Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ] | Technology appraisal guidance |
| Timrepigene emparvovec for treating choroideremia [ID3916] | Technology appraisal guidance |
| Tinnitus | Quality standard |
| Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy TS ID 10672 | Technology appraisal guidance |
| Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation TS ID 11841 | Technology appraisal guidance |
| Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer TS ID 10759 | Technology appraisal guidance |
| Tiratricol for treating Allan–Herndon–Dudley syndrome TS ID 11794 | Technology appraisal guidance |
| Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683 | Technology appraisal guidance |
| Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID 5077] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer TS ID 10687 | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157] | Technology appraisal guidance |
| Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer TS ID 10693 | Technology appraisal guidance |
| Tocilizumab for treating systemic sclerosis (ID1396) | Technology appraisal guidance |
| Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767] | Technology appraisal guidance |
| Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845 | Technology appraisal guidance |
| Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy TS ID 11862 | Technology appraisal guidance |
| Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer TS ID 11857 | Technology appraisal guidance |
| Transperineal laser ablation (TPLA) for treating lower urinary tract symptoms of benign prostatic hyperplasia using a ultra-micro invasive approach. | Interventional procedures guidance |
| Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910 | Technology appraisal guidance |
| Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934] | Technology appraisal guidance |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments TS ID 11824 | Technology appraisal guidance |
| Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine TS ID 11855 | Technology appraisal guidance |
| Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540] | Technology appraisal guidance |
| Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772 | Technology appraisal guidance |
| TriageHF Plus | Diagnostics guidance |
| Tricvalve Bi-caval valve implantation for Edge 2 Edge repair | Interventional procedures guidance |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781 | Technology appraisal guidance |
| Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer ID4061 | Technology appraisal guidance |
| Ublituximab for treating relapsing–remitting multiple sclerosis TS ID 11795 | Technology appraisal guidance |
| Ultrasound-guided percutaneous laser ablation for primary and secondary liver tumours | Interventional procedures guidance |
| Upadacitinib for treating giant cell arteritis TS ID 10495 | Technology appraisal guidance |
| Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806] | Technology appraisal guidance |
| Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes TS ID 11877 | Technology appraisal guidance |
| Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879] | Technology appraisal guidance |
| Venglustat for treating gangliosidoses in people 2 years and over TS ID 11896 | Technology appraisal guidance |
| Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy TS ID 10612 | Technology appraisal guidance |
| Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment TS ID 11907 | Technology appraisal guidance |
| Vilobelimab for treating COVID-19 TS ID 11815 | Technology appraisal guidance |
| Vonicog alfa for treating haemorrhage or treating and preventing surgical bleeding in people with von Willebrand disease when desmopressin is ineffective or not suitable TS ID 10266 | Technology appraisal guidance |
| Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807] | Technology appraisal guidance |
| Vulnerable populations: strategies for tackling inequalities | Quality standard |
| WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467 | Technology appraisal guidance |
| Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer TS ID 11803 | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765 | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477 | Technology appraisal guidance |
| Zolbetuximab with chemotherapy for untreated CLDN 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction cancer TS ID 10579 | Technology appraisal guidance |
| Zuranolone for treating severe postnatal depression TS ID 11863 | Technology appraisal guidance |